NCT07219238 - Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE) | Biotech Hunter

Enrollment

175

Participants

Timeline

Start Date

March 31, 2026

Primary Completion Date

June 30, 2029

Study Completion Date

August 31, 2029

Conditions

Colorectal CancerGastric CancersOvarian CancersPancreatic Ductal Adenocarcinoma

Interventions

DRUG

GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)

Attenuation correction CT will commence after the administration of GEH300079 (68Ga), and immediately before the PET acquisition. The PET acquisition will encompass the participant's vertex through mid-thighs. Images will be acquired at 60 ±5 minutes post injection, with a scan duration of approximately 20 to 30 minutes.

Trial Locations (2)

17176

Karolinska Universitetssjukhuset, Stockholm

49503

BAMF Health, Grand Rapids